Update in Waldenström’s Macroglobulinemia

Cancer therapy & Oncology International Journal
doi 10.19080/ctoij.2016.02.555590
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Juniper Publishers

Related search

Massive Bone Marrow Necrosis Associated With Waldenström’s Macroglobulinemia

Acta Haematologica Polonica
OncologyHematology
2018English

How Recent Advances in Biology of Waldenström’s Macroglobulinemia May Affect Therapy Strategy

Current Oncology Reports
Oncology
2019English

Polymorphisms in FcγRIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenström’s Macroglobulinemia

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2005English

L265P Mutation of the MYD88 Gene Is Frequent in Waldenström’s Macroglobulinemia and Its Absence in Myeloma

PLoS ONE
Multidisciplinary
2013English

MYD88 L265P Is a Marker Highly Characteristic Of, but Not Restricted To, Waldenström’s Macroglobulinemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2013English

Diagnostic Tools of Waldenström’s Macroglobulinemia – Best Possibilities for Non-Invasive and Long-Term Disease Monitoring

Klinicka Onkologie
Oncology
2017English

Idelalisib in a Patient With Refractory Waldenström’s Macroglobulinemia Complicated by Anuric Renal Failure: A Case Report

Journal of Medical Case Reports
Medicine
2018English

Bilateral Sudden Sensorineural Hearing Loss in Waldenström’s Macroglobulinemia: Case Report and Review of the Literature

Annals of Otology and Neurotology
2020English

Modelling the Effectiveness of Ibrutinib Versus Physician’s Choice (PC) in Relapsed or Refractory (RR) Waldenström’s Macroglobulinemia (WM) Within England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy